CERBA-HEALTHCARE
7.3.2023 12:22:36 CET | Business Wire | Press release
Cerba HealthCare, a leading global player in medical diagnosis, has been exploring new alternatives to transport biological samples that combine low carbon footprint, shorter time-to-results for patients and prescribers while allowing every patient to benefit from the analytical quality of large capacity laboratory platforms in a timely manner.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230307005636/en/
©Delivrone 2023
Over the past couple of weeks, France and Italy, two major affiliates of the Group, hosted drone-enabled sample transport and successfully performed their experimental flights in different conditions.
Jérôme Sallette, Chief Scientific Officer at Cerba HealthCare, comments: “Following the use cases we described in our white paper, the drone flight we experimented in Normandy with Cerballiance is a first step toward a broader and more sustainable approach of our logistic mix for sample transportation. It illustrates the long-standing drive for innovation within the Group and by 2024, we plan to identify how drones will prove an efficient complementary way of carrying biological samples”.
“Last week Cerba HealthCare Italia performed the first drone flight with biological samples embedded, involving some of the medical centers around the Metropolitan City of Milan, specifically in the two sites located in the cities of Opera and Rozzano” adds Stefano Massaro, Chief Executive Officer of Cerba HealthCare Italia. “We are dealing with the first air transport of blood samples not yet tested, experimented by the use of a drone. The result of this adventure today makes us confident and eager to pursue the path of innovation as a landmark of a leading quality service for patients”.
- To access the French flight video: https://youtu.be/rjy0e1kMluM
- To access the Italian flight video: https://www.youtube.com/watch?v=-wOCDJipasc
- To access the white paper: https://www.cerbahealthcare.com/en/drones-medical-logistics-opportunities-and-challenges
About Cerba HealthCare
Cerba HealthCare, a leading global player in medical diagnostics, aims to support the evolution of health systems towards more prevention. It draws on more than 50 years of expertise in clinical pathology to better assess the risk of diseases development, detect and diagnose diseases earlier, and optimize the effectiveness of personalized medicine.
Every day, on five continents, the Group's 15,000 employees sustain the transformation of medicine, driven by one deep conviction: to advance diagnosis is to advance health.
Cerba HealthCare, enlightening health.
Additional information is available at www.cerbahealthcare.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005636/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Announces Amendment to Maximize Size of Normal Course Issuer Bid9.3.2026 12:00:00 CET | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX: KXS) today announces that, further to its previously announced intention to maximize the size of its normal course issuer bid (the “NCIB”), it has received approval from the Toronto Stock Exchange (the “TSX”) to amend (the “Amendment”) the NCIB, effective on March 11, 2026 (the “Effective Date”), to increase the maximum number of common shares (the “Shares”) that may be repurchased from 1,403,042, representing 5% of the Company’s issued and outstanding Shares as at October 31, 2025, to 2,799,843, representing 10% of the Company’s “public float” as at October 31, 2025, the maximum amount allowable under the rules of the TSX. No other terms of the NCIB have been amended. The Company has already invested US$54 million under its current NCIB. At the average price paid to date for the Shares under the current NCIB, repurchasing 10% of the Shares would represent an additional investment of approximately US$284 million. In its February 4, 2026
Ki Reply and Data Reply Lay the Strategic Foundation for AI Innovation at Siemens Healthineers with “Cerebra”9.3.2026 10:53:00 CET | Press release
Ki Reply and Data Reply, the Reply Group companies specialised respectively in AI-powered software development and data-driven solutions, have partnered with the “CRM Excellence” department of medical technology company Siemens Healthineers to develop “Cerebra“, an advanced AI platform designed to deliver rapid, relevant insights across marketing and sales. The concept proved so successful that “Cerebra” was evolved into an Agent Factory, which now standardises, simplifies, and accelerates the deployment of AI agents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260309083025/en/ To support labour-intensive manual research in marketing, and sales, Siemens Healthineers now leverages “Cerebra“, an AI-powered knowledge platform that uses specialised AI agents to consolidate internal and external data. In the fast-moving and highly regulated medical technology market, the ability to analyse information accurately and quickly is
AMINA Becomes First Regulated Bank on 21X, Europe’s First Fully Regulated DLT Trading and Settlement Venue9.3.2026 08:30:00 CET | Press release
Along with Tokeny, the combined tokenisation suite creates a complete tokenisation infrastructure, from regulated custody to onchain trading and settlement AMINA Bank AG (“AMINA”), a Swiss Financial Market Supervisory Authority (FINMA)-regulated crypto bank with global reach, today announces it has become a listing sponsor on 21X, the first fully regulated distributed ledger technology trading and settlement system (DLT TSS) in the European Union. AMINA is the first regulated bank to join the 21X ecosystem as a listing sponsor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260309758719/en/ AMINA, 21X and Tokeny partner for end-to-end solution Combined with AMINA’s existing collaboration with Tokeny for onchain asset issuance, the partnership creates a complete tokenisation infrastructure that addresses a major constraint of institutional adoption: the absence of an end-to-end pathway connecting regulated traditional asset c
GigaDevice Strengthens Global Presence at Embedded World 2026, Showcasing System-Level Innovations for Humanoid Robotics, Industry, and Edge AI9.3.2026 08:00:00 CET | Press release
Wide range of demonstrations on display at Hall 5, 5-129 throughout the March 10-12 show GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced its participation at Embedded World 2026 (Hall 5, Booth 5-129), with the strong presence at the show demonstrating the company’s commitment to the global market and the strategic emphasis that it has placed on the EMEA region, reinforcing its ambition to empower customers with advanced embedded solutions. “Embedded World is a cornerstone of our global engagement strategy,” said Dr. Reiner Jumpertz, GigaDevice VP and General Manager in the EMEA region. “This year, we are not only showcasing our technical excellence but also highlighting our evolution into a system-level enabler, a trusted partner that supports customers in building smarter, more connected applications.” “By combining our high-performance GD32 MCUs, industry-proven Flash memory, and a
Galderma Introduces Cetaphil AM/PM Antioxidant Serums, a New Science-Driven Defense and Recovery System for Sensitive Skin9.3.2026 07:00:00 CET | Press release
Cetaphil’s new AM/PM Serums are powered by unique Gallic-AOX Power™ Technology, a patent-pending antioxidant complex clinically designed to sync to your skin’s circadian rhythm and support skin resilience Delivers advanced antioxidant protection by day1 and accelerated repair by night, with visible results in as little as 7 days2 In global testing, Gallic Acid demonstrated 2x greater antioxidant efficacy than Vitamin C3 Co-developed with dermatologists and rigorously tested for sensitive skin to deliver high performance without compromising tolerance Galderma (SIX: GALD) today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is launching its new Cetaphil AM/PM Antioxidant Serums, a breakthrough daily system clinically designed to defend skin by day and support accelerated repair by night for sensitive, stressed skin. While antioxidant serums are a cornerstone of modern skincare, the category has largely been developed without sensitive sk
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom